Table 1 Patient Characteristics and clinical results (n = 76)
20 ml of ropivacaine Group (n = 39) | 25 ml of ropivacaine Group (n = 37) | P-value | |
|---|---|---|---|
Age, mean (SD),y | 39.33(14) | 39.89(11) | 0.86 |
Sex (male/female), n | 23/16 | 24/13 | 0.30 |
Weight, mean (SD), kg | 65.14(10.82) | 67.65(11.22) | 0.33 |
Height, mean (SD), cm | 165.92(8.13) | 167.35(7.96) | 0.43 |
BMI, mean (SD), kg/m2 | 23.61(3.26) | 24.15(3.11) | 0.24 |
ASA physical status (I/II), n | 27/12 | 24/13 | 0.93 |
Types of surgery, n | 0.95 | ||
Hemorrhoids | 16 | 19 | |
Perianal abscess | 8 | 8 | |
Anal fistula | 8 | 5 | |
Anal polyp | 7 | 5 | |
The block performance time, min | 4.31(0.85) | 4.32(1.18) | 0.94 |
The block onset time, min | 3.67(1.68) | 3.65(2.19) | 0.97 |
The block perfect time, min | 9.57(3.26) | 11.24(3.83) | 0.11 |
The block duration time, min | 409.92(74.15) | 434.84(73.86) | 0.27 |